Gizem Erensoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gizem Erensoy has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Stubelius
Division of Chemical Biology, Department of Life Sciences, Chalmers University of Technology, Gothenburg 412 96, Sweden
4 shared publications Ula von Mentzer
Division of Chemical Biology, Department of Life Sciences, Chalmers University of Technology, Gothenburg 412 96, Sweden
2 shared publicationsA.-K. Hultgård Ekwall
The Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication- Ammar D. Elmezayen
Department of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, Istanbul, Turkey
1 shared publication Anna-Karin Hultgård Ekwall
The Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden
1 shared publicationChang-Guo Zhan
1 shared publication
Latest Publications
- Open Access
- 10 December 2025
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (3) , 661-683
Advances in phenylboronic acid and phenylboronic ester-based responsive systems for precision medicine
PBA and PBE derived materials have played a crucial role in advanced healthcare technologies such as diagnostics, therapeutics and theranostics that can be useful for personalized therapies based on biomarkers of diseases.
- 10 December 2025
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (3) , 661-683
Open AccessAdvances in phenylboronic acid and phenylboronic ester-based responsive systems for precision medicine
PBA and PBE derived materials have played a crucial role in advanced healthcare technologies such as diagnostics, therapeutics and theranostics that can be useful for personalized therapies based on biomarkers of diseases.
- Open Access
- 25 May 2024
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 7 (6) , 3810-3820
Dynamic Release from Acetalated Dextran Nanoparticles for Precision Therapy of Inflammation
Polymer-based nanoparticles (NPs) that react to altered physiological characteristics have the potential to enhance the delivery of therapeutics to a specific area. These materials can utilize biochemical triggers, such as low pH, which is prone to happen locally in an inflammatory microenvironment due to increased cellular activity. This reduced pH is neutralized when inflammation subsides. For precise delivery of therapeutics to match this dynamic reaction, drug delivery systems (DDS) need to not only release the drug (ON) but also stop the release (OFF) autonomously. In this study, we use a systematic approach to optimize the composition of acetalated dextran (AcDex) NPs to start (ON) and stop (OFF) releasing model cargo, depending on local pH changes. By mixing ratios of AcDex polymers (mixed NPs), we achieved a highly sensitive material that was able to rapidly release cargo when going from pH 7.4 to pH 6.0. At the same time, the mix also offered a stable composition that enabled a rapid ON/OFF/ON/OFF switching within this narrow pH range in only 90 min. These mixed NPs were also sensitive to biological pH changes, with increased release in the presence of inflammatory cells compared to healthy cells. Such precise and controllable characteristics of a DDS position mixed NPs as a potential treatment platform to inhibit disease flare-ups, reducing both systemic and local side effects to offer a superior treatment option for inflammation compared to conventional systems.
- 25 May 2024
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 7 (6) , 3810-3820
Open AccessDynamic Release from Acetalated Dextran Nanoparticles for Precision Therapy of Inflammation
Polymer-based nanoparticles (NPs) that react to altered physiological characteristics have the potential to enhance the delivery of therapeutics to a specific area. These materials can utilize biochemical triggers, such as low pH, which is prone to happen locally in an inflammatory microenvironment due to increased cellular activity. This reduced pH is neutralized when inflammation subsides. For precise delivery of therapeutics to match this dynamic reaction, drug delivery systems (DDS) need to not only release the drug (ON) but also stop the release (OFF) autonomously. In this study, we use a systematic approach to optimize the composition of acetalated dextran (AcDex) NPs to start (ON) and stop (OFF) releasing model cargo, depending on local pH changes. By mixing ratios of AcDex polymers (mixed NPs), we achieved a highly sensitive material that was able to rapidly release cargo when going from pH 7.4 to pH 6.0. At the same time, the mix also offered a stable composition that enabled a rapid ON/OFF/ON/OFF switching within this narrow pH range in only 90 min. These mixed NPs were also sensitive to biological pH changes, with increased release in the presence of inflammatory cells compared to healthy cells. Such precise and controllable characteristics of a DDS position mixed NPs as a potential treatment platform to inhibit disease flare-ups, reducing both systemic and local side effects to offer a superior treatment option for inflammation compared to conventional systems.
- Open Access
- 22 February 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Cationic Nanoparticle Interactions with Catabolic Cartilage Modify Macrophage Cytokine Production
Cationic nanoparticles (NPs) have emerged as promising candidates for intra-articular drug delivery, showcasing their potential as efficient carriers. However, despite their evident utility, many studies neglect to investigate their interactions with the extracellular matrix (ECM). This oversight represents a significant gap in our understanding, particularly in the context of osteoarthritis (OA) treatment, where viable therapeutic options are limited. The clinical translation of functionalize drug carriers for OA has been hindered, in part, by our incomplete comprehension of how these materials interact with and respond to the pathological environment. This study aims to address this gap by examining how cationic NPs interact with ECM components in an ex vivo OA cartilage explant model. By comparing the behavior of smaller (<10nm) and larger (~270 nm) cationic NPs and subjecting them to explants preconditioned with OA-specific catabolic enzymes, we observed multifaceted effects on ECM integrity and biomolecule conformation. All NP-biomolecule complexes induced differential cytokine production from stimulated macrophages. Smaller polyamidoamine (PAMAM) nanocarriers reduced glycosaminoglycan (GAG) release from explants but increased proinflammatory cytokine stimulation under pathological conditions, while larger poly lactic(co-glycolic)acid(PLGA)/polyethylenimine(PEI)-based nanocarriers maintained GAG release but induced a significantly lower proinflammatory cytokine response. Collagenase-induced OA-mimicking preconditioning produced distinct profiles across the NP panel in GAG interactions and cytokine production. The findings from these studies underscore the significance of tailored nanocarrier approaches to achieve optimal therapeutic efficacy for OA and other complex diseases.
- 22 February 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCationic Nanoparticle Interactions with Catabolic Cartilage Modify Macrophage Cytokine Production
Cationic nanoparticles (NPs) have emerged as promising candidates for intra-articular drug delivery, showcasing their potential as efficient carriers. However, despite their evident utility, many studies neglect to investigate their interactions with the extracellular matrix (ECM). This oversight represents a significant gap in our understanding, particularly in the context of osteoarthritis (OA) treatment, where viable therapeutic options are limited. The clinical translation of functionalize drug carriers for OA has been hindered, in part, by our incomplete comprehension of how these materials interact with and respond to the pathological environment. This study aims to address this gap by examining how cationic NPs interact with ECM components in an ex vivo OA cartilage explant model. By comparing the behavior of smaller (<10nm) and larger (~270 nm) cationic NPs and subjecting them to explants preconditioned with OA-specific catabolic enzymes, we observed multifaceted effects on ECM integrity and biomolecule conformation. All NP-biomolecule complexes induced differential cytokine production from stimulated macrophages. Smaller polyamidoamine (PAMAM) nanocarriers reduced glycosaminoglycan (GAG) release from explants but increased proinflammatory cytokine stimulation under pathological conditions, while larger poly lactic(co-glycolic)acid(PLGA)/polyethylenimine(PEI)-based nanocarriers maintained GAG release but induced a significantly lower proinflammatory cytokine response. Collagenase-induced OA-mimicking preconditioning produced distinct profiles across the NP panel in GAG interactions and cytokine production. The findings from these studies underscore the significance of tailored nanocarrier approaches to achieve optimal therapeutic efficacy for OA and other complex diseases.
- Open Access
- 15 July 2022
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 30 (10) , 1356-1364
Synovial fluid profile dictates nanoparticle uptake into cartilage - implications of the protein corona for novel arthritis treatments
- 15 July 2022
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 30 (10) , 1356-1364
Open AccessSynovial fluid profile dictates nanoparticle uptake into cartilage - implications of the protein corona for novel arthritis treatments
- 6 July 2020
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 24 (4) , 436-451
Synthesis, in silico studies and cytotoxicity evaluation of novel 1,3,4-oxadiazole derivatives designed as potential mPGES-1 inhibitors
- 6 July 2020
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 24 (4) , 436-451
Synthesis, in silico studies and cytotoxicity evaluation of novel 1,3,4-oxadiazole derivatives designed as potential mPGES-1 inhibitors
- 13 May 2016
- Published by Marmara University in Marmara Pharmaceutical Journal
- Vol. 20 (3) , 275
A validated spectrophotometric method for determination of formoterol fumarate dihydrate in bulk and dosage form using methyl orange as ion pair reagent
A validated spectrophotometric method for determination of formoterol fumarate dihydrate in bulk and dosage form using methyl orange as ion pair reagent
- 13 May 2016
- Published by Marmara University in Marmara Pharmaceutical Journal
- Vol. 20 (3) , 275
A validated spectrophotometric method for determination of formoterol fumarate dihydrate in bulk and dosage form using methyl orange as ion pair reagent
A validated spectrophotometric method for determination of formoterol fumarate dihydrate in bulk and dosage form using methyl orange as ion pair reagent
- 1 January 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 469 (3) , 743-747
Discovery of conjugated thiazolidinone-thiadiazole scaffold as anti-dengue virus polymerase inhibitors
- 1 January 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 469 (3) , 743-747
Discovery of conjugated thiazolidinone-thiadiazole scaffold as anti-dengue virus polymerase inhibitors